Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of adalimumab in Japanese subjects with active ankylosing spondylitis
2014-004532-18Phase 3
- Sponsor
- Abbott Laboratories
- Start
- Nov 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in ankylosing spondylitis (AS), sponsored by Abbott Laboratories. Primary endpoint: ASAS 20 response (primary).
02
Drugs
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2014-004532-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004532-18.